AMGN AMGEN INC
Biological Products, (No Diagnostic Substances) · Nasdaq · SEC CIK 318154 · Fiscal year ends 12/31
Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters
Growth
TTM revenue YoY8.2%
TTM net income YoY34.1%
TTM EPS YoY33.4%
Revenue 3-yr CAGR13.2%
Net income 3-yr CAGR7.5%
Margins
Gross margin70.9%
Operating margin32.4%
Net margin24.1%
FCF margin24.6%
EBITDA margin39.4%
Returns
ROE78.4%
ROA10.1%
ROIC (approx.)19.5%
Asset turnover0.42x
Leverage & solvency
Liabilities / assets85.1%
Debt / equity3.76x
Current ratio1.48x
Interest coverage4.78x
Cash quality & payout
Operating cash flow / net income1.28x
Accruals ratio-2.8%
Payout ratio57.1%
Capex / revenue6.3%
Factor history charts and full statement history on Pro 🔒
Financial statements
| Line item | FY20252025-12-31 | FY20242024-12-31 | FY20232023-12-31 | FY20222022-12-31 | FY20212021-12-31 |
|---|---|---|---|---|---|
| Income statement | |||||
| Revenue | $36.75B | $33.42B | $28.19B | $26.32B | $25.98B |
| Cost of revenue | $12.04B | $12.86B | $8.45B | $6.41B | $6.45B |
| Gross profit | $24.71B | $20.57B | $19.74B | $19.92B | $19.52B |
| R&D expense | $7.27B | $5.96B | $4.78B | $4.43B | $4.82B |
| SG&A expense | $7.05B | $7.10B | $6.18B | $5.41B | $5.37B |
| Operating income | $9.08B | $7.26B | $7.90B | $9.57B | $7.64B |
| Interest expense | $2.75B | $3.15B | $2.88B | $1.41B | $1.20B |
| Pretax income | $8.98B | $4.61B | $7.86B | $7.35B | $6.70B |
| Income tax | $1.26B | $519.00M | $1.14B | $794.00M | $808.00M |
| Net income | $7.71B | $4.09B | $6.72B | $6.55B | $5.89B |
| EBITDA | $14.25B | $12.85B | $11.97B | $12.98B | $11.04B |
| EPS (basic) | 14.33 | 7.62 | 12.56 | 12.18 | 10.34 |
| EPS (diluted) | 14.23 | 7.56 | 12.49 | 12.11 | 10.28 |
| Dividends declared per share | 9.66 | 9.13 | 8.64 | 7.95 | 7.22 |
| Weighted avg. shares (diluted) | 542.00M | 541.00M | 538.00M | 541.00M | 573.00M |
| Balance sheet | |||||
| Cash & equivalents | $9.13B | $11.97B | $10.94B | $7.63B | $7.99B |
| Short-term investments | — | — | $0 | $1.68B | $48.00M |
| Receivables | $9.57B | $6.78B | $7.27B | $5.56B | $4.89B |
| Inventory | $6.22B | $7.00B | $9.52B | $4.93B | $4.09B |
| Current assets | $29.06B | $29.03B | $30.33B | $22.19B | $19.39B |
| PP&E, net | $7.91B | $6.54B | $5.94B | $5.43B | $5.18B |
| Goodwill | $18.68B | $18.64B | $18.63B | $15.53B | $14.89B |
| Intangibles | $22.28B | $27.70B | $32.64B | $16.08B | $15.18B |
| Total assets | $90.59B | $91.84B | $97.15B | $65.12B | $61.16B |
| Current liabilities | $25.49B | $23.10B | $18.39B | $15.69B | $12.18B |
| Short-term debt | $4.60B | $3.55B | $1.44B | $1.59B | $87.00M |
| Long-term debt | $50.01B | $56.55B | $63.17B | $37.35B | $33.22B |
| Total debt | $54.60B | $60.10B | $64.61B | $38.95B | $33.31B |
| Total liabilities | $81.93B | $85.96B | $90.92B | $61.46B | $54.47B |
| Shareholders' equity | $8.66B | $5.88B | $6.23B | $3.66B | $6.70B |
| Net debt | $45.48B | $48.13B | $53.67B | $31.32B | $25.32B |
| Shares outstanding | 538.80M | 536.90M | 535.40M | 534.00M | 558.30M |
| Cash flow statement | |||||
| Operating cash flow | $9.96B | $11.49B | $8.47B | $9.72B | $9.26B |
| Capital expenditure | $1.86B | $1.10B | $1.11B | $936.00M | $880.00M |
| Free cash flow | $8.10B | $10.39B | $7.36B | $8.79B | $8.38B |
| Investing cash flow | -$1.94B | -$1.05B | -$26.20B | -$6.04B | $733.00M |
| Financing cash flow | -$10.86B | -$9.41B | $21.05B | -$4.04B | -$8.27B |
| Depreciation & amortization | $5.17B | $5.59B | $4.07B | $3.42B | $3.40B |
| Stock-based compensation | $494.00M | $530.00M | $431.00M | $401.00M | $341.00M |
| Dividends paid | $5.12B | $4.83B | $4.56B | $4.20B | $4.01B |
| Share buybacks | $0 | $200.00M | $0 | $6.36B | $4.97B |
Free plan shows the latest 5 periods; Pro shows all 19 🔒
· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.
Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-18 06:30.